CASI Pharmaceuticals (CASI) has released an update.
CASI Pharmaceuticals reported a 12% decrease in third-quarter revenue in 2024 compared to the previous year but saw a significant 96% increase from the previous quarter, reaching $7.8 million. The company is making strides in its strategic focus with the approval of a clinical trial in China for a key therapeutic and progress in the U.S. drug application process. However, CASI is facing challenges, including a net loss of $8.4 million and ongoing litigation against former employees.
For further insights into CASI stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
